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Abstract
Stroke is the fifth leading cause of death in the U.S., with more than 100,000 deaths annually. 
There are a multitude of risks associated with stroke, including aging, cardiovascular disease, 
hypertension, Alzheimer’s disease (AD), and immune suppression. One of the many challenges, 
which has so far proven to be unsuccessful, is the identification of a cost-effective diagnostic or 
prognostic biomarker for stroke. Alkaline phosphatase (AP), an enzyme first discovered in the 
1920s, has been evaluated as a potential biomarker in many disorders, including many of the co-
morbidities associated with stroke. This review will examine the basic biology of AP, and its most 
common isoenzyme, tissue nonspecific alkaline phosphatase (TNAP), with a specific focus on the 
central nervous system. It examines the preclinical and clinical evidence which supports a 
potential role for AP in stroke and suggest potential mechanism(s) of action for AP isoenzymes in 
stroke. Lastly, the review speculates on the clinical utility of AP isoenzymes as potential blood 
biomarkers for stroke or as AP-targeted treatments for stroke patients.
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1.0 Stroke: Current Biomarkers and Therapeutics
1.1 Stroke
Stroke is one of the leading causes of death and disability in the U.S., accounting for 
approximately 1 in every 19 death (Benjamin et al. 2018). When stroke occurs, oxygen and 
glucose perfusion are restricted in specific brain regions, leading to cell death and the 
subsequent loss of memory and motor function. The size of the stroke often correlates with 
the extent of disability, assessed through a simplified modified Rankin scale questionnaire 
(Bruno et al. 2013). There are two different types of stroke. Hemorrhagic strokes occur when 
a weakened blood vessel leaks out into the brain tissue. The second, and most common type 
of stroke, is known as ischemic stroke, where blood flow to a certain area of the brain is 
blocked from a blood clot or plaque lesion. Ischemic stroke can be embolic, where a clot or 
plaque lesion forms in another area within the body then travels and gets stuck in the brain, 
or thrombotic, where a clot forms within one of the vessels that supplies blood to the brain 
(Dirnagl et al. 1999).
Strokes commonly occur in the elderly and occur more often in women than men. Risk 
factors for stroke include: hypertension, high cholesterol, atherosclerosis, smoking, 
excessive drinking, and diabetes. Although reperfusion of the ischemic brain is the goal for 
treatment, intense inflammation and further tissue damage occurs during the reperfusion 
process. Clinical evidence shows that an evolution of brain injury often occurs in the hours 
to days following a stroke, which allows only a small time-frame for successful therapeutic 
intervention. Within minutes of a stroke, the neurons at the core of the infarct that are closest 
to the region of oxygen or glucose deprivation undergo necrotic cell death. The necrotic core 
is surrounded by an area of tissue, the penumbra, that is less severely impacted by the lack 
of blood flow and remains metabolically active; functionality of the penumbra may be lost 
but is salvageable. Clinicians focus on restoring the functionality of the penumbra region as 
part of their stroke treatment (Dirnagl et al. 1999; Dirnagl and Endres 2014; Benjamin et al. 
2018).
1.2. Stroke Biomarkers and Therapeutics
Although numerous biomarkers have been assessed for their use in stroke, none so far have 
proven to be reliable enough to use as a standard in the clinic. Several current or emerging 
stroke biomarkers are described in Table 1. There is a critical need to develop faster and less 
expensive diagnostic testing tools for stroke, such as the use of blood biomarker panels. 
Despite growing efforts to identify blood biomarkers that may be useful for the 
determination and differentiation of stroke, there are no current specific biomarker 
recommendations for use in the clinic. Likewise, stroke therapeutics are limited. Since the 
approval of recombinant tissue plasminogen activator (rtPA) in 1996, no other drug has 
received FDA approval to treat stroke (The National Institute of Neurological Disorders and 
Stroke rt-PA Stroke Study Group 1995; Adams et al. 1996; Report of the Quality Standards 
Subcommittee of the American Academy of Neurology 1996). The quest for new stroke 
therapeutics has been plagued by numerous clinical trial failures, due in large part to the 
discrepancy between the positive results in preclinical animal models of stroke, and the 
subsequent negative findings when the same therapeutics are tested in human clinical trials 
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(Bushnell et al. 2006; Jickling and Sharp 2015). One possible candidate for use as a 
diagnostic and prognostic marker for stroke is alkaline phosphatase (AP). Several studies 
have indicated that AP may be actively beneficial or detrimental in many inflammatory and 
ischemic settings (Heemskerk et al. 2009; Davidson et al. 2012; Shimizu et al. 2013a; Liu et 
al. 2016; Gdara et al. 2018). This review will discuss the practicality of exploring AP as a 
potential marker for stroke and how AP can be manipulated for therapeutic purposes.
2.0 Alkaline Phosphatase
2.1 Alkaline Phosphatase Genetics and Cell Biology
Alkaline phosphatase (AP) was first discovered in 1923, when Dr. Robert Robison described 
the presence of an enzyme abundant in animal bone that rapidly hydrolyzed 
hexosemonophosphoric acid into phosphoric acid (Robison 1923). AP has since been shown 
to play a significant role in human bone mineralization, confirmed by many cases of 
hypophosphatasia, a rare metabolic inherited disease caused by a mutation in the ALPL gene 
(Moore et al. 1990; Whyte et al. 2009; Barvencik et al. 2011). There are four isoenzymes of 
AP in humans, i.e. intestinal (IAP), placental (PLAP), germinal (GCAP), and tissue 
nonspecific (TNAP) (Millan 1986; Weiss et al. 1986; Berger et al. 1987; Millan and Manes 
1988), which can be reviewed in (Van Hoof and De Broe 1994; Buchet et al. 2013). The first 
three isoenzymes are expressed in the tissues for which they are named and each is encoded 
by a unique homologous gene loci in humans: ALPI, ALPP, ALPPL2, and ALPL (Harris 
1990; Buchet et al. 2013). The TNAP protein, also known as bone/liver/kidney AP, is 
expressed by a variety of tissues including multiple cell types in the brain. TNAP is the most 
abundant isoenzyme collected from blood, where approximately 50-60% is derived from 
bone, 30% from the intestines, and 10-20% from the liver (Moss 1982).
APs belong to the ectophosphatase enzyme family and are localized in multiple mammalian 
cells and tissues (Bannister and Romanul 1963; Kang and West 1982; Paiva et al. 1983; 
Mori and Nagano 1985; Van Hoof and De Broe 1994; Champion et al. 2003). This class of 
enzymes is anchored on the cell plasma membrane surface by a glycosylphosphatidylinositol 
(GPI) moiety which allows them to act on substrates in the extracellular space. APs can be 
localized in the lipid rafts of the plasma membrane outer leaflet via the C-terminus to the 
GPI, found as a soluble protein in the serum, or as a vesicle-associated protein in the 
extracellular space. GPI-anchored AP proteins can be shed from the plasma membrane by 
cleavage from phosphatidylinositol-phospholipases to take on the soluble form in blood 
(Low and Zilversmit 1980; Low 1987).
Abnormal levels of AP can result in hypophosphatasia (Waymire et al. 1995; Razazizan et 
al. 2013; Sebastian-Serrano et al. 2016). Thus, AP has a well-characterized role in skeletal 
mineralization, and speculation into other physiological function(s) of AP enzymes has 
generated the most interest with regard to host defense. The role in inflammation is due, in 
part, to its ability to neutralize endotoxins through dephosphorylation of the lipid-A moiety 
converting it to the non-toxic monophosphoryl product, and it may target bacterial 
components like CpG DNA and flagellin (Poelstra et al. 1997a, b; Chen et al. 2010). 
Similarly, AP also deactivates ATP, which when upregulated can act as an immunological 
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danger signal, while maintaining homeostasis of gut bacteria (Poelstra et al. 1997a; Malo et 
al. 2010; Peters et al. 2015). Figure 1 summarizes AP’s actions in the periphery.
Another complication of abnormal AP serum levels in Akp2 (mouse TNAP gene) null mice 
is epilepsy. Nearly three decades after its initial discovery, Shimizu showed histochemical 
evidence of TNAP in the nervous system of several animal models (Shimizu 1950). 
However, the roles of TNAP in neurological disorders remains poorly understood. Since 
TNAP has been shown to interact with multiple substrates and molecules, it is highly likely 
that TNAP exhibits multiple functions in the brain (Waymire et al. 1995; Whyte et al. 1995; 
Ermonval et al. 2009). Depending on the cell type, TNAP can be transiently or constitutively 
expressed within the central nervous system, which suggests multiple mechanisms of gene 
expression across the many cell types in the brain and spinal cord (Narisawa et al. 1994; 
MacGregor et al. 1995; Fonta 2004; Langer et al. 2008). Some data suggest that TNAP may 
play a role in neurotransmitter metabolism (Fonta 2004; Fonta et al. 2005; Balasubramaniam 
et al. 2010), and Hanics et al. used TNAP null mice to show that TNAP deficiency leads to 
decreased brain myelination and synaptogenesis. These findings suggest that TNAP plays an 
important role in brain development and that TNAP deficiency can contribute to many forms 
of neurological dysfunction, including epilepsy (Hanics et al. 2012). Figure 2 depicts 
numerous presumed functions of AP in the CNS.
3.0 Alkaline Phosphatase as a Biomarker for Stroke
3.1 Serum Alkaline Phosphatase as a Diagnostic Tool
Normal blood AP levels vary depending on sex and age, although AP levels typically display 
a wide range within these respective groups (Fenuku and Foli 1975; Lester 1977; Molla et 
al. 1990; Magnusson et al. 1995; Zierk et al. 2017; Wanjian et al. 2017; Li et al. 2018). For 
example, naturally high levels of AP are seen in children because their bones are still 
growing. Thus, clinicians and researchers rely on an average range of “normal” AP levels 
rather than a specific number. In general, abnormal AP levels are indicative there is some 
condition or disorder that has disrupted homeostasis. Some temporary conditions may also 
affect AP levels, including pregnancy, bone fractures, and taking specific medications 
(Herbeth et al. 1981; Rodin et al. 1989; Okesina et al. 1995; Choi and Pai 2000; Sadighi et 
al. 2008). For example, pregnancy can cause AP levels to be elevated 2-3 times that of 
normal due to an increase in placental AP (Okesina et al. 1995; Choi and Pai 2000). 
Alternatively, a patient’s serum total AP levels can also be increased following a meal due to 
an increase in the intestinal isoenzyme; however, this is typically a very transient elevation 
that quickly returns to normal levels if the patient is otherwise healthy (Sukumaran and 
Bloom 1953; Khan et al. 2016).
Elevated levels of AP are also indicative of numerous disorders including excessive skeletal 
mineralization, Paget’s disease, tumors, and, potentially, Alzheimer’s disease (AD) (Naik 
etal. 1977; Lampl et al. 1990; Vardy et al. 2012). The magnitude of AP elevation tends to 
reflect the extent of dysfunction. Typically, AP tends to be most markedly elevated due to 
hepatic obstruction, hepatitis, and other liver diseases (Schlaeger 1975; Paritpokee et al. 
1999). During certain conditions, AP levels can increase greater than 3-fold and are 
measured at 10-12 times the upper limit of normal, particularly in bone disorders (Mayo 
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Clinic; Moss 1982; Jassam et al. 2009; Teitelbaum et al. 2011). Interestingly, AP levels are 
generally normal during osteoporosis (Kelly et al. 1967). Although less clinically explored, 
observations of abnormal AP serum levels have also been associated with neurological 
disorders such as AD (Kellett et al. 2011; Vardy et al. 2012).
The standard clinical chemistry AP tests used in laboratory medicine report total AP enzyme 
activity rather than the amount of total AP protein. For simplicity, this review will use AP 
levels to refer to AP activity, as is commonly done in clinical practice. Thus, when used as 
part of a typical comprehensive metabolic panel, this test represents the sum of all soluble 
AP isoenzyme activity in serum or plasma. Clinicians often interpret elevated levels of AP 
with pathological conditions related to bone and liver disorders because the majority of AP 
detected in the blood comes from the liver and bone; however, this test can also indicate 
intestinal or parathyroid disease (Mayo Clinic; Posen et al. 1967; Yoneda et al. 1988; Tuin et 
al. 2009). Additional testing can also be performed to determine the source of possible 
dysregulation, including liver (L1 and L2), bone (B1, B2, B/I, and B1x), intestinal, and 
placental tissues. Normal AP ranges for these various isoenzymes also differ. Clinicians can 
continue to monitor elevated AP levels as the patient undergoes treatment to indicate that a 
treatment may or may not be working (Wolf 1978; Van Hoof and De Broe 1994).
3.2 Alkaline Phosphatase as a Putative Biomarker for Neurological Injury
Researchers have used AP activity as a brain microvessel marker in primates for decades, 
and its presence has been described in the cerebral parenchyma of both young and old 
monkeys (Friede 1966; Bell and Ball 1985; Anstrom et al. 2002; Fonta and Imbert 2002; 
Fonta 2004; Fonta et al. 2005). Primate, mouse, rat, and human brains have been used to 
demonstrate that expression of TNAP activity can be found in brain endothelial cells and 
neurons (Charegaonkar and Rindani 1961; Meyer Peter 1963; Friede 1966; Narisawa et al. 
1994; Nishihara et al. 1994; Fonta 2004; Ermonval et al. 2009; Brun-Heath et al. 2011). 
Numerous studies indicate that AP RNA expression, protein levels, or enzyme activity may 
vary significantly between primates and rodents. In primate brains, AP activity can be 
detected in one or a few cortical layers, but not in all areas, while in rodent brains, AP 
activity is more scattered with variable levels of intensity (Brun-Heath et al., 2011).
Several studies have demonstrated that TNAP is elevated in many neurological disorders, 
including some types of brain injury (Yamashita et al. 1989) and AD (Gong et al. 1993; 
Kellett et al. 2011; Vardy et al. 2012). TNAP has been shown to play a role in tau 
phosphorylation. Vardy et al. showed that TNAP is increased in both human brain tissue and 
plasma from patients with familial and sporadic AD (Vardy et al. 2012). Also, in patients 
with various brain injuries, the concentration of serum AP correlated with functional 
outcome and increased TNAP had an inverse correlation with cognitive function (Yamashita 
et al. 1989; Kellett et al. 2011; Vardy et al. 2012). Among patients with brain tumors, those 
that also had pulmonary carcinomatous meningitis were found to have elevated AP levels in 
their cerebrospinal fluid (CSF), while AP concentrations in control patients with epilepsy 
and stroke were decreased in comparison to the brain tumor group (Lampl et al. 1990). 
Increased liver AP levels were described in patients with nontraumatic intracranial 
hemorrhages (Meythaler et al. 1998).
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Elevated serum AP levels may also underscore brain-peripheral immune interactions during 
stroke, as Muscari et al. found evidence that the liver participates in the response to acute 
ischemic stroke by releasing enzymes (Muscari et al., 2014). AP levels have been shown to 
increase in relation to large-volume cerebral white matter hyperintensities and may be 
associated with multi-cerebral microbleeds in ischemic stroke patients (Ryu et al. 2014; Lee 
et al. 2015; Liu et al. 2016). While Lee et al. suggest that increased serum AP may be a 
marker for impaired cerebral microcirculation, Liu et al. were unable to replicate these 
results in their study (Lee et al. 2015; Liu et al. 2016). The authors state these differences 
may be due to the small number and clinical characteristics of their subjects, as well as the 
statistical methods used in both studies (Liu et al. In contrast, a smaller number of studies 
have reported a decrease in serum TNAP in other neurological disorders. For example, 
TNAP levels were found to be significantly decreased in traumatic brain injury (Arun et al. 
2015). Additionally, AP activity was found to be neither significantly elevated nor reduced 
in aging patients alone (Vardy et al. 2012) or in patients with multiple sclerosis (Hanna et al. 
1997; Tremlett et al. 2006). These findings underscore the importance of continued research 
to elucidate the mechanisms under which AP or TNAP levels are elevated or reduced in 
neurological disorders.
3.3 Alkaline Phosphatase as a Diagnostic and Prognostic Stroke Biomarker
Prior clinical studies have explored AP as a diagnostic and prognostic marker to assess 
stroke risk by correlating indices of AP activity such as: dysfunctional bone metabolism 
(Barnadas et al. 2014; Namba et al., 2017), cardiovascular disease (Webber et al. 2010; Kim 
et al. 2017; Makil et al. 2017), cancer (Giessen et al. 2014; Barnadas et al. 2014; Hammerich 
et al. 2017) and periodontitis (Kunjappu et al. 2012). More importantly, elevated AP levels 
in stroke patients have been correlated with stroke severity and hypertension (Pratibha et al. 
2014; Tan et al. 2017). While the underlying molecular mechanisms to support this 
association are unclear, other studies have provided additional support for this observation. 
In patients with coronary artery disease who underwent percutaneous coronary intervention, 
those with the highest AP levels had the greatest risk of 3-year mortality or secondary 
outcomes (cardiac mortality, nonfatal myocardial infarction, stent thrombosis or stroke) 
(Ndrepepa et al. 2017). A study using a cohort of patients with preserved kidney function 
reported AP as an independently useful tool for predicting mortality and stroke recurrence 
(Zong et al. 2018). Another study of acute ischemic stroke patients revealed that patients 
within the highest serum AP quartile had the highest incidence of early mortality (Zhong et 
al. 2018). Lastly, another cohort of patients who experienced a transient ischemic attack 
showed that those with increased serum AP levels on admission were more likely to have 
subsequent ischemic stroke events (Uehara et al. 2018). A smaller minority of studies do not 
support any associations between AP serum and stroke. For example, AP levels did not 
correlate with extracranial or intracranial arterial stenosis patients with ischemic stroke (Kim 
et al. 2013). Overall, evidence from most reported studies suggests a significant association 
between AP and various stroke outcomes. Table 2 describes the major direct and indirect 
mechanisms that support a role for elevated AP levels in the pathophysiology of stroke.
The majority of AP biomarker studies have explored the use of AP as a prognostic tool. 
Nearly 30 years ago, Yamashita et al. suggested AP may be useful in predicting prognosis of 
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brain damage in patients with postresuscitation encephalopathy, ruptured cerebral 
aneurysms, acute subdural hematoma and contusion, and non-traumatic intracerebral 
hemorrhage (Yamashita et al. 1989). A large retrospective study assessing serum AP levels 
in primary sclerosing cholangitis patients at the time of diagnosis and one year after 
diagnosis demonstrated that AP may hold prognostic value in prediction of endpoint-free 
survival (de Vries et al. 2016). Clinical studies have shown that increased AP is associated 
with risk of cardiovascular disease, one of the many risk factors for stroke (Tonelli et al. 
2009; Park et al. 2013; Wannamethee et al. 2013; Kunutsor et al. 2014). Elevated AP levels 
are correlated with more vascular deaths and recurrent vascular events, suggesting that AP 
may be a predictor for mortality in stroke patients (Pratibha et al. 2014; Tan et al. 2017). 
Abnormal AP has been associated with many of the risk factors leading to stroke, including 
heavy drinking (Ebuehi and Asonye 2007; Shimizu et al. 2013a), obesity (Menahan et al. 
1985; Golik et al. 1991), and hypertension (Shimizu et al. 2013b). Elevated AP has been 
shown to correlate with poor functional outcome and mortality in cardiovascular disease 
(Park et al. 2013; Wannamethee et al. 2013; Karabulut et al. 2014; Kunutsor et al. 2014) and 
in stroke patients (Ryu et al. 2010; Kim et al. 2013; Tan et al. 2016). Investigators theorize 
that the negative association between AP levels and stroke outcome may be linked to the fact 
that increased AP levels are associated with increased inflammation and enhanced vascular 
calcification leading to atherosclerosis (Tonelli et al. 2009; Kim et al. 2013; Ryu et al. 2014). 
Preclinical and clinical studies can be designed to address this question.
4.0 Alkaline Phosphatase-Based Therapeutics in Stroke
4.1 Therapeutic Administration of Alkaline Phosphatase
Exogenous administration of AP has been shown to have beneficial effects on the outcome 
of numerous inflammatory disorders in humans and animal models of the associated disease, 
including sepsis (Ebrahimi et al., 2011; Heemskerk et al., 2009; Verweij et al., 2004; 
Pickkers et al., 2009), ulcerative colitis (Lukas et al., 2010; Tuin et al., 2009), necrotizing 
enterocolitis (Whitehouse et al. 2010), and multiple sclerosis (Huizinga et al. 2012). These 
studies and a number of others which have shown positive disease outcomes using AP 
therapeutics are described in Table 3. For example, pre-symptomatic AP administration 
reduced signs of neurological distress in experimental autoimmune encephalomyelitis (EAE) 
mice (Huizinga et al. 2012). Systemic inflammation is also common after surgery and often 
complicates surgical outcomes. In some cases, exogenous administration of AP may be 
useful to reduce post-operative care requirements. Davidson et al. showed that AP’s ability 
to neutralize inflammatory substrates illustrates that it may be protective against systemic 
inflammation in post-operative patients (Davidson et al., 2012). Oral administration of AP to 
ulcerative colitis patients for one week also improved clinical response scores and decreased 
CRP levels (Lukas et al., 2010). Alternatively, intravenous administration of AP decreased 
plasma creatinine levels in patients with renal complications from severe sepsis or septic 
shock (Heemskerk et al. 2009; Pickkers et al. 2012). Phase II clinical trials have already 
shown the benefits of using bovine-derived intestinal AP in a subset of critically ill patients 
(Heemskerk et al. 2009). Administration of a human recombinant AP (recAP) consisting of 
a placental/intestinal AP hybrid resulted in positive phase I clinical trial outcome in a subset 
of septic patients (Kiffer-Moreira et al. 2014; Peters et al. 2016b), that is supported by 
Brichacek and Brown Page 7













effective recAP therapeutic efficacy from preclinical models (Peters et al. 2016a, 2017). 
Thus, the use of TNAP or recombinant AP molecules may provide a viable therapeutic 
option for patients as well as provide insights on AP’s mechanism(s) of action in 
cerebrovascular disease.
4.2 AP Therapeutic Inhibition of Alkaline Phosphatase
In contrast, a smaller set of studies have proposed a therapeutic approach that inhibits TNAP. 
An emerging concept which supports a role for AP in vascular disease is that elevated serum 
AP, most likely due to elevated TNAP activity, promotes vascular calcification and leads to 
increased risk of cardiovascular disease and stroke. To prevent these outcomes, 
administration of an AP inhibitor has been suggested as one potential therapeutic option. 
Research from Pratibha and colleagues suggests that administration of AP inhibitors could 
be used to prevent cerebral ischemia in high-risk populations (Pratibha et al. 2014). A study 
in stroke-prone rats found beneficial effects against cardiovascular disease complications 
using a traditional fungal medicine and found that the number of capillaries that expressed 
AP in the heart was significantly decreased compared to untreated rats. Typically, TNAP is 
minimally localized to cardiac microvessels in comparison to its levels in cerebral 
microvessels (Koyama et al. 2006). Some of the better-known AP inhibitors, including 
tetramisole and levamisole, are no longer used in the clinic due to lack of AP isoenzyme 
specificity and serious neurological side effects associated with chronic treatment (Nowak et 
al. 2015). Sheen et al. have made efforts towards screening for promising TNAP inhibitors. 
One of their more-promising candidates, SBI-425, has been shown to reduce aortic 
calcification and prolong life in TNAP-overexpressing mice (Sheen et al. 2015). Overall, AP 
inhibitors have proven to be useful for reducing vascular calcification, an important risk 
factor for the development of stroke. Thus, it is imperative that we identify the 
circumstances when AP, and more specifically TNAP, is beneficial and when it is harmful. 
The identification of these mechanisms will prove crucial in the development of AP-based 
therapeutics to prevent or to treat cerebrovascular disorders such as stroke.
5.0 Potential Mechanistic Targets for Alkaline Phosphatase in Stroke
The proposed mechanism of action for AP’s therapeutic utility in stroke include 
enhancement of BBB integrity, relief of inflammation, and promotion of vascular 
homeostasis, as shown in Figure 3. ATP release is an important consequence of stroke-
associated inflammation, induced by multiple brain cell types, especially BBB endothelial 
cells. AP enhancement with exogenous PLAP, IAP, or recombinant alkaline phosphatase 
(recAP) may help to decrease inflammation by catalyzing the reaction of pro-inflammatory, 
toxic ATP to anti-inflammatory, nontoxic adenosine. This in turn activates neuroprotective 
signaling cascades which limit inflammation, enhance BBB integrity, and promote vascular 
homeostasis.
5.1 Blood-Brain Barrier Permeability
Increased BBB permeability is likely to have a role in the putative association between AP 
and stroke. TNAP is expressed in brain endothelial cells and may play an important role in 
BBB maintenance and integrity (El Hafny et al. 1996; Deracinois et al. 2012), as well as 
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transportation of proteins, including insulin, across the barrier (Calhau et al. 2002). The 
cerebral microvasculature is protected by astrocytes, pericytes, and the extracellular matrix 
that surrounds the vessels (ladecola and Nedergaard 2007). The primary proteins involved in 
keeping the cerebral environment separate from the rest of the body are tight junctions, and 
the dysfunction of these proteins leads to BBB breakdown and neuronal cell death. 
Following stroke, toxic proteases, cytokines, and free radicals form to aid in the removal of 
dead cells, however these molecules also cause tissue damage and participate in BBB 
disruption (Yang and Rosenberg 2011; Jiang et al. 2018). Rabbits with diabetic ketoacidosis 
exhibited increased inducible nitric oxide synthase (NOS) activity and decreased AP activity 
levels in brain endothelium (Zhu et al. 2004). One emerging concept suggests that TNAP 
may be released into the circulation to neutralize inflammation produced in response to 
damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns 
(PAMPs). The release of membrane-bound TNAP as soluble TNAP into the circulation may 
result in a compromised BBB (Pike et al. 2015). In vitro evidence for a direct role for TNAP 
in the regulation of BBB integrity was demonstrated by Deracinois and colleagues 
(Deracinois et al. 2012, 2015). Treatment of cultured brain capillary endothelial cells with 
the nonspecific AP inhibitor, levamisole, increased permeability to a fluorescent tracer and 
reorganized the actin cytoskeleton; removal of levamisole reversed the increase in 
permeability and cytoskeletal disruption (Deracinois et al. 2015). These results support a 
critical role for TNAP in the integrity of the cerebral microvasculature. TNAP’s 
mechanism(s) of action at the BBB are also summarized in Figure 2.
5.2 Neuroinflammation
Elevated serum AP is a highly characteristic part of the inflammatory response in multiple 
disorders. Prior studies have suggested that abnormal AP levels contribute to the 
development of cerebral small vessel disease and cardiovascular disease (Tonelli et al. 2009; 
Park et al. 2013; Wannamethee et al. 2013; Kunutsor et al. 2014; Lee et al. 2015). Huizinga 
et al. proposed that AP has a role in limiting neuroinflammation by interfering with immune 
activation through neutralization of LPS and endogenous substrates such as ATP. They found 
that AP administration during the priming phases of EAE reduced neurological signs of 
multiple sclerosis (MS) (Huizinga et al. 2012). Post-stroke infections are very common in 
stroke patients, particularly respiratory and urinary tract infections (Langhorne et al. 2000; 
Vernino et al. 2003). Thus, it is likely that mechanisms related to infection-induced 
inflammation are also involved in the initiation of AP upregulation in stroke patients. 
Increasing evidence suggests that infection often precedes or triggers chronic neurological 
diseases such as MS (Buljevac et al. 2002). AP’s natural ability to neutralize inflammatory 
substrates may prove that it has a beneficial role in slowing neuroinflammation. Recent 
studies have shown the importance of the gut-brain axis in MS, and demonstrate that 
microbial infection can activate myelin-reactive T cells in the CNS (Nogai et al. 2005; Berer 
et al. 2011). ATP, an endogenous damage associated molecular pattern (DAMP) signal, is 
upregulated by multiple cells in response to stress, and has been shown to activate microglia 
in response to brain injury (Davalos et al. 2005), and can also trigger oligodendrocyte 
excitotoxicity (Matute et al. 2007). In contrast, chronic liver disease also increased AP 
activity in rat brains (Dhanda et al. 2018). Elevated brain AP levels found in both CNS and 
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systemic examples of infection-induced inflammation strongly suggests that similar 
neuroinflammatory mechanisms are also present in the pathophysiology of stroke.
5.3 Altered Vascular Homeostasis
The disruption of cerebral microvascular homeostasis is another common feature of stroke. 
In contrast to other studies which suggest that serum AP levels are elevated post-stroke, 
Shimizu et al. speculated that altered vascular homeostasis plays a role in the association 
between lower AP levels and increased risk of stroke (Shimizu et al. 2013a). Endothelial 
progenitor cells (EPCs) have been shown to circulate in peripheral blood and contribute to 
maintenance of the vasculature (Asahara et al. 1997). Previous research has shown that 
reduced levels of EPCs predict atherosclerotic disease progression (Schmidt-Lucke et al. 
2005). Another study showed an association between reduced EPCs and an increased 
number of infarctions, but no significant correlation with atherosclerosis; this finding is 
likely due to the multiple risk factors and cell types that contribute to vascular dysfunction 
(Taguchi et al. 2004). Since EPCs also contribute to vascular repair, it is likely that a 
reduction in these cells may lead to increased risk of stroke (Shimizu et al. 2013a). 
Thickening of the cerebral vessel walls via increased collagen represents a normal feature of 
aging. In leukoaraiosis, which is caused by chronic ischemia, venous collagenosis is further 
increased and may be due, in part, to altered TNAP activity in cerebral microvessels (Brown 
et al. 2002). Lee et al. also speculate that the association between AP and indicators of 
cerebral small vessel disease includes issues with vascular calcification and microcirculation 
impairment (Lee et al. 2015). It is hypothesized that vascular calcification leads to stiff 
vessel walls and the resultant microcirculatory dysfunction may lead to myocardial 
ischemia, and by extension, cerebrovascular dysfunction and the onset of cerebral ischemia 
(Sigrist and McIntyre 2008). Alternatively, other studies have suggested that elevated bone 
AP levels may accelerate the development of cardiovascular disease through vascular 
calcification, presumably due to impaired vascular homeostasis (Shioi et al. 2002; Shimizu 
et al. 2013a). Thus, there are multiple putative mechanisms through which altered TNAP 
activity in endothelial cells and EPCs could impact cerebrovascular homeostasis to increase 
stroke risk or negatively impact post-stroke outcomes.
6.0 Conclusion
Although AP is a ubiquitous enzyme expressed in numerous tissues, a comprehensive 
understanding of its molecular and cellular mechanisms of action remains elusive. Emerging 
clinical evidence supports the potential utility of AP as a rapid, cost-effective blood 
biomarker to be used singly or as part of a biomarker panel in stroke patients. In light of the 
proposed mechanism in Figure 3, the complex cell biology of AP represents is an important 
consideration for the development of targeted AP-based biomarkers and therapeutics for 
stroke. It will be critically important to understand the circumstances under which AP 
administration or AP inhibition are beneficial as well as detrimental. Harnessing this 
knowledge may represent an important milestone in the development of novel therapeutic 
agents for stroke.
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Figure 1. Role of alkaline phosphatase isoenzymes in the periphery:
AP plays an important role in the physiology and pathophysiology of many organ systems. 
AP’s actions in the gastrointestinal, immune, and cardiovascular systems are most relevant 
to the systemic immune response in ischemic stroke. A.) In the gastrointestinal system, both 
TNAP and intestinal AP play an important anti-inflammatory role by neutralizing gut 
microbes. B.) Immune system: Numerous peptides, lipids, and other molecules are 
recognized by antigen-presenting cells (APC) to activate T-cells in the periphery. During T-
cell activation adenosine triphosphate (ATP) is released, contributing to the inflammatory 
environment. TNAP can convert ATP to the anti-inflammatory molecule adenosine through 
stepwise conversion of ATP to adenosine diphosphate (ADP) and adenosine monophosphate 
(AMP). C.) Cardiovascular system: An excess of bone AP contributes to vascular 
calcification, leading to stiff muscle walls and, eventually, atherosclerosis.
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Figure 2. Role of tissue nonspecific alkaline phosphatase (TNAP) in the central nervous system:
TNAP is expressed in neurons, microglia, astrocytes, oligodendrocytes, and is highly 
expressed in brain endothelial cells. TNAP is localized in the lipid rafts of the plasma 
membrane outer leaflet via its C-terminus to the GPI. It can also be found as a soluble 
protein in the serum or as a vesicle-associated protein in the extracellular space. TNAP may 
have a role in blood-brain barrier (BBB) breakdown, neuroinflammation, and vascular 
dysfunction in stroke and other neurological disorders. Inflammatory mediators such as 
reactive oxygen species (ROS), proteases, and inflammatory cytokines, promote the 
breakdown of junctional proteins at the BBB. The loss of junctional proteins weakens the 
BBB and allows activated T-cells, antigen-presenting cells (APC), other leukocytes, and pro-
inflammatory mediators to traverse the BBB, with bidirectional movement between the brain 
parenchyma and cerebral circulation. These mechanisms play an important role in the 
pathophysiology of ischemic stroke and other neuroinflammatory disorders.
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Figure 3. Proposed mechanism of action for implementation of alkaline phosphatase-based 
therapeutics in stroke:
An important consequence that results from the induction of stroke-associated inflammatory 
pathways is increased ATP release in multiple brain cell types, particularly in BBB 
endothelial cells. AP administration, via placental alkaline phosphatase (PLAP), intestinal 
alkaline phosphatase (IAP), or recombinant alkaline phosphatase (recAP) may help to 
decrease inflammation by facilitating the hydrolysis of pro-inflammatory, toxic ATP to anti-
inflammatory, nontoxic adenosine. Binding of adenosine to its receptors has been shown to 
activate neuroprotective signaling cascades which limit inflammation, enhance BBB 
integrity, and promote vascular homeostasis.
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Table 1.
Current or potential biomarkers as diagnostic or prognostic tools for stroke.





↑at stroke onset ↓ = poor prognosis (Gandolfi et al., 2017)
Myokines
Irisin ↑ = good prognosis (Gandolfi et al., 2017)
Myostatin ↑ = muscle wasting (Gandolfi et al., 2017)
Follistatin-like 1 (FSTL1) ↑ = good prognosis (Gandolfi et al., 2017)
Cytokines
IL-6, TNF-α, IL-10, IL-
4, IL-17, IL-23, TGF-α,
IL-15, IL-19, IL-33, IL-
1β
↑ at stroke onset Varies
(Beghetti et al. 2003; Sonderer and 
Katan Kahles 2015;











↑ at stroke onset Varies (Bonaventura et al., 2016)
Neuropeptides
Neuropeptide Y ↑ = good prognosis (Gandolfi et al., 2017)
Proenkephalin ↑ = poor prognosis (Gandolfi et al., 2017)
Growth Factors Vascular endothelialgrowth factor (VEGF) ↑ at stroke onset (Gandolfi et al., 2017)
Immune Cells




changes after stroke ↑ = good prognosis (Gandolfi et al., 2017)
Natural Killer (NK)
cells
↑ in brain at stroke
onset (Gandolfi et al., 2017)
T and B Lymphocytes; CD4+ &
CD8+ T cells;
γδ-T cells
↑ at stroke onset;
peripheral pattern
changes after stroke
(Gandolfi et al., 2017; Bonaventura 
et al., 2016)
Microglia ↑ at stroke onset (Bonaventura et al., 2016)
Neutrophils ↑ at stroke onset (Bonaventura et al., 2016)
Dendritic cells ↓ during stroke (Gandolfi et al., 2017)
Protein & Enzyme
CRP, GTT, GPT,
bilirubin ↑ at stroke onset
Varies; typically ↑ =
poor prognosis
(Beghetti etal. 2003;
Pineda et al. 2008; Tang et al. 
2013; Luo et al. 2013; Muscari et 
al. 2014;
Sonderer and Katan Kahles 2015;
Bonaventura et al. 2016)
AP
Usually ↑ at stroke
onset, but some
variation
↑ = poor prognosis
(Cheung et al. 2008; Metwalli et al. 
2014; Muscari et al. 2014; Ryu et 




↓ = ↑ risk factor of
carotid
atherosclerosis
(Gandolfi et al., 2017)
miRNA-146a, −181b,
and −30a Varies ↓ = ↑ neuroprotection
(Martinez and Peplow 2016; 
Gandolfi et al. 2017;
Khoshnam et al. 2017)
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Biomarker Group Molecule or Cell Diagnostic Ability Prognostic Ability Reference
miRNA-107, −128b, and −153 ↑ at stroke onset (Martinez and Peplow, 2016; Khoshnam et al., 2017)
Reactive Oxygen
Species Antioxidant enzymes
↑ at stroke onset =
redox imbalance
(Bonaventura et al., 2016; 







↑ at stroke onset (Bonaventura et al., 2016)
Key: ↑ = increase; ↓ = decrease
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Table 2.
Direct and indirect effects of stroke on alkaline phosphatase levels
Condition Mechanism Related to Stroke Reference
Ischemia/hypoxia ↑ cellular stress → ↑ ATP release →↑ tissue damage
(Beghetti et al. 2003; Kunutsor et al. 2014; Peters et al. 2014; 
Khoshnam et al. 2017)
Inflammation
↑ cellular stress → ↑ ATP release →↑ tissue 
damage (Kunutsor et al. 2014; Peters et al. 2014; Khoshnam et al. 2017)
↑ inflammatory cytokines →↑ tissue damage (Beghetti et al. 2003; Kunutsor et al. 2014; Peters et al. 2014; Bonaventura et al. 2016; Khoshnam et al. 2017)
↑ NO levels →↑ tissue damage (Kunutsor et al. 2014; Peters et al. 2014; Bonaventura et al. 2016; Khoshnam et al. 2017)
Liver damage ↑ enzyme release (Muscari et al., 2014)
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Table 3:
Positive Therapeutic Outcomes in Preclinical and Clinical AP Studies
Type of AP 
Therapy
Study
Population Injury or Disease Model Outcome Ref.
AP Administration
PLAP Mouse LPS
PLAP administration improved 
sepsis survival, possibly by 
halting its’ development
(Bentala et al. 
2002)
PLAP Mouse LPS
PLAP treatment improved 
survival and lowered NO levels in 
septic mice
(Verweij et al. 
2004)
IAP Mouse & pig LPS
IAP administration attenuates LPS 
toxicity up to 80%, resulting in 
increased survival and inhibits 




IAP treatment reduced local and 
systemic inflammatory responses, 
as well as distant damage in the 
liver and lungs
(van Veen et al. 
2005)
IAP Sheep Sepsis
Administration of IAP in fecal 
peritonitis-induced septic shock 
improved gas exchange, decreased 
blood IL-6 levels, and increased 
survival time
(Su et al. 2006)
IAP Phase IIa clinical trial Sepsis
Infusion of IAP in severe sepsis 
and septic shock patients inhibits 
the upregulation of renal iNOS, 
leading to reduction of NO 
metabolite production and 
attenuated tubular enzymuria, 
resulting in overall improved renal 
function







IAP administration significantly 
improved renal function in septic 
patients
(Pickkers et al. 
2009)
IAP Rat Inflammatory bowel disease
IAP treatment alleviates epithelial 
layer damage associated with DSS 
in rat intestines
(Tuin et al. 2009)
IAP Open-label, first-in-patient exploratory trial Ulcerative colitis
IAP administration was associated 
with short-term improvement in 
UC disease activity
(Lukas et al. 2010)
IAP Rat NEC Supplemental IAP has a protective role in experimental NEC
(Whitehouse et al. 
2010)
IAP Mouse Antibiotictreatment
IAP supplementation increased 
growth of commensal bacteria 
leading to restored gut microbiota 
lost to antibiotic treatment
(Malo et al. 2010)
IAP Mouse Sepsis
IAP treatment enhanced survival 
and reduced organ damage in 
septic mice
(Ebrahimi et al. 
2011)
IAP





Overall, IAP treatment improves 
renal function in patients with 
severe sepsis or sepsis shock with 
AKI
(Pickkers et al. 
2012)
IAP Rat Inflammatory bowel disease
Intrarectally administered IAP in 
models of rats colitis resulted in a 
lower colonic weight and tissue 
damage score; normalized 
(Martinez-Moya et 
al. 2012)
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Type of AP 
Therapy
Study
Population Injury or Disease Model Outcome Ref.
expression of neutrophil markers 
and IL-1β; and counteracted 
bacterial translocation
IAP Mouse Multiple Sclerosis
Pre-symptomatic treatment of 
EAE with IAP reduces 
neurological symptoms
(Huizinga et al. 
2012)
IAP Rat NEC
IAP supplementation decreased 
histologic injury scores and 
barrier permeability in the ileum 
of rat pups with NEC
(Rentea et al. 
2012)
IAP Mouse Metabolicsyndrome
IAP supplementation inhibited 
absorption of endotoxins and 
improved the lipid profile in mice, 
resulting in prevention or reversal 
of metabolic syndrome
(Kaliannan et al. 
2013)
IAP Rat NEC
IAP treatment decreased iNOS 
and TNF-α expression, and 
decreased LPS translocation into 
the serum of infant rats
(Rentea et al. 
2013)
IAP Rat NEC
IAP supplementation decreased 
intestinal injury and inflammation, 
including TNF-α, IL-6 and iNOS 
by LPS in preterm rat intestine







supplementation resulted in 
weight maintenance, reduced 
clinical severity, reduced gut 
inflammation, and improved 
survival following infection
(Alam et al. 2014)
recAP Rat LPS
recAP treatment has renal 
protective effects from LPS-
induced damage
(Peters et al. 2015)
recAP Rat Renal ischemia and reperfusion; LPS
recAP exerted a clear renal 
protective anti-inflammatory 
effect
(Peters et al. 
2016a)
AP Inhibition
Levamisole Prospective clinical trial Colon cancer
The addition of levamisole to 
5FU-adjuvant therapy improved 
survival in stage II and III colon 
cancer patients
(Taal et al. 2001)
L-Phen Rat LPS
Suggest that lAPs in the 
gastrointestinal tract reduce LPS 
content in serum
(Koyama et al. 
2002)
SBI-425 Mouse Medial vascular calcification
TNAP inhibition significantly 
reduced aortic calcification and 
cardiac hypertrophy, and extended 
lifespan over vehicle-treated 
controls
(Sheen et al. 2015)
SBI-425 Mouse Hypophosphatasia
TNAP inhibition reduces calcium 
and lipid levels to improve the 
course of coronary atherosclerosis
(Romanelli et al. 
2017)
SBI-425 Mouse Pseudoxanthoma elasticum (PXE)
TNAP inhibition attenuated 
calcification, altering disease 
development and progression in 
vivo
(Ziegler et al. 
2017)
PLAP: placental alkaline phosphatase; IAP: intestinal alkaline phosphatase; LPS: lipopolysaccharide; NO: nitric oxide; iNOS: inducible nitric 
oxide synthase; DSS: dextran sodium sulfate; NEC: Necrotizing enterocolitis; AKI: acute kidney injury; EAE: experimental autoimmune 
encephalomyelitis; recAP: human recombinant alkaline phosphatase; L-Phen: L-phenylalanine
Metab Brain Dis. Author manuscript; available in PMC 2020 February 01.
